Oculis Holding AG (NASDAQ:OCS) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Oculis Holding AG (NASDAQ:OCS) have earned a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $39.44.

OCS has been the subject of several recent research reports. Guggenheim decreased their price target on shares of Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, June 1st. HC Wainwright upped their price objective on Oculis from $26.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, September 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research note on Friday, July 17th. Needham & Company LLC decreased their target price on Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a report on Monday, June 1st. Finally, Stifel Nicolaus decreased their target price on Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a report on Monday, June 1st.

Hedge Funds Weigh In On Oculis

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Koshinski Asset Management Inc. purchased a new stake in shares of Oculis during the first quarter worth approximately $238,000. Himension Capital Singapore PTE. LTD. purchased a new position in Oculis in the first quarter worth approximately $503,000. Y Intercept Hong Kong Ltd acquired a new position in Oculis during the 1st quarter worth approximately $776,000. Squarepoint Ops LLC grew its holdings in Oculis by 326.4% during the 2nd quarter. Squarepoint Ops LLC now owns 61,605 shares of the company’s stock worth $854,000 after acquiring an additional 47,158 shares in the last quarter. Finally, Bank of America Corp DE increased its position in shares of Oculis by 9.1% in the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock valued at $1,855,000 after purchasing an additional 5,813 shares during the last quarter. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Stock Down 5.8%

Shares of OCS opened at $9.41 on Friday. The stock has a market capitalization of $545.63 million, a PE ratio of -5.41 and a beta of 0.52. Oculis has a 1 year low of $9.21 and a 1 year high of $34.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.35 and a current ratio of 8.35. The company’s 50-day simple moving average is $11.80 and its 200-day simple moving average is $18.39.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. The business had revenue of $0.38 million during the quarter. Analysts forecast that Oculis will post -2.01 earnings per share for the current fiscal year.

Oculis Company Profile

Oculis is a clinical-stage biopharmaceutical company focused on developing ophthalmic therapies for eye diseases and vision loss. The company uses proprietary drug-delivery technologies designed to improve the delivery of treatments to specific tissues in the eye, with the goal of offering effective and convenient alternatives to injections or other invasive procedures.

Oculis’ pipeline includes OCS-01, a topical eye-drop formulation of dexamethasone being developed for diabetic macular edema and inflammation following ocular surgery.